Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072436 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT00072436: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00072436 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072436, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of gemcitabine hydrochloride and alvocidib in treating patients with solid tumors. Drugs used in chemotherapy, such as gemcitabine hydrochloride and alvocidib, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells
Interventions
- OTHER pharmacological study
- DRUG gemcitabine hydrochloride
- DRUG alvocidib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2003-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072436
The ClinicalTrials.gov registry entry for NCT00072436 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pharmacological study is the first listed.
NCT00072436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072436 about?
NCT00072436 is a clinical study titled "Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors". This phase I trial is studying the side effects and best dose of gemcitabine hydrochloride and alvocidib in treating patients with solid tumors. Drugs used in chemotherapy, such as gemcitabine hydrochloride and alvocidib, use different ways to stop tumor cells from dividing so they stop growing or d...
What is the current status of trial NCT00072436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2003-09.
What interventions are being tested in trial NCT00072436?
The interventions under investigation include: pharmacological study (OTHER), gemcitabine hydrochloride (DRUG), alvocidib (DRUG).
Who is sponsoring clinical trial NCT00072436?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.